Telaglenastat
CB-839
Glutaminase inhibitor
Evidence Score
60
Selective, orally bioavailable inhibitor of glutaminase (GLS). Blocks the conversion of glutamine to glutamate, cutting off the primary anaplerotic fuel source for SDH-deficient cells with disrupted TCA cycles.
With the TCA cycle disrupted at Complex II, SDH-deficient cells become addicted to glutamine for anaplerosis and lipid synthesis via reductive carboxylation.
Upstream event:
TCA cycle disruption at succinate → fumarate step
Downstream effects:
GLS
Glutaminase (kidney isoform)
Converts glutamine to glutamate for TCA anaplerosis. SDH-deficient cells are glutamine-addicted. Target of telaglenastat (CB-839).
UniProt: O94925
Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.
Coming in Phase 3
Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.